Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Payment for Contingent Consideration Liability, Financing Activities

Payment for Contingent Consideration Liability, Financing Activities at other companies

Hillman Solutions Corp. logo
Hillman Solutions Corp.HLMN
$77K+2.7%
ePlus logo
ePlusPLUS
$0—
AvePoint, Inc. logo
AvePoint, Inc.AVPT
$0-100%
The Baldwin Insurance Group, Inc. logo
The Baldwin Insurance Group, Inc.BWIN
$0-100%
TFX
TeleflexTFX
$58K+3.6%
Henry Schein logo
Henry ScheinHSIC
$0-100%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's payment for contingent consideration liability, financing activities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's payment for contingent consideration liability, financing activities?
Supernus Pharmaceuticals (SUPN) reported payment for contingent consideration liability, financing activities of $0 in Q1 2026.
How has Supernus Pharmaceuticals's payment for contingent consideration liability, financing activities changed year-over-year?
Supernus Pharmaceuticals's payment for contingent consideration liability, financing activities decreased by 100.0% year-over-year, from $20.1M to $0.